Clinical Trial Update: Topical Bimatoprost Solution 0.03%in Stable Vitiligo [Phase 4]

View source ↗

Summary

Phase 4 trial of topical bimatoprost 0.03% for stable vitiligo has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• Bimatoprost (bimatoprost)

Snippet

Sponsor: Gian Sagar Medical College and Hospital | Conditions: Vitiligo, Repigmentation | Phase 4 | Status: WITHDRAWN